ES2995959T3 - Methods for the detection and treatment of lung cancer - Google Patents
Methods for the detection and treatment of lung cancer Download PDFInfo
- Publication number
- ES2995959T3 ES2995959T3 ES18752036T ES18752036T ES2995959T3 ES 2995959 T3 ES2995959 T3 ES 2995959T3 ES 18752036 T ES18752036 T ES 18752036T ES 18752036 T ES18752036 T ES 18752036T ES 2995959 T3 ES2995959 T3 ES 2995959T3
- Authority
- ES
- Spain
- Prior art keywords
- lung cancer
- sftpb
- pro
- cea
- cyfra21
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B5/20—Probabilistic models
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Physiology (AREA)
- Probability & Statistics with Applications (AREA)
- Data Mining & Analysis (AREA)
- Evolutionary Computation (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Signal Processing (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Artificial Intelligence (AREA)
- Public Health (AREA)
- Software Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762456731P | 2017-02-09 | 2017-02-09 | |
| PCT/US2018/017704 WO2018148600A1 (en) | 2017-02-09 | 2018-02-09 | Methods for the detection and treatment of lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2995959T3 true ES2995959T3 (en) | 2025-02-11 |
Family
ID=63107741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18752036T Active ES2995959T3 (en) | 2017-02-09 | 2018-02-09 | Methods for the detection and treatment of lung cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US12504430B2 (enExample) |
| EP (2) | EP3580560B1 (enExample) |
| JP (1) | JP7311417B2 (enExample) |
| KR (2) | KR102827354B1 (enExample) |
| CN (2) | CN110291397A (enExample) |
| CA (1) | CA3053116A1 (enExample) |
| ES (1) | ES2995959T3 (enExample) |
| WO (1) | WO2018148600A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108139381A (zh) | 2015-06-26 | 2018-06-08 | 百奥马克癌症系统公司 | 肺癌检测方法 |
| ES2995959T3 (en) | 2017-02-09 | 2025-02-11 | Univ Texas | Methods for the detection and treatment of lung cancer |
| WO2021016711A1 (en) * | 2019-07-29 | 2021-02-04 | Biomark Cancer Systems Inc. | Method of discriminating lung cancer patients |
| GB2603051B (en) | 2020-01-30 | 2023-04-26 | Prognomiq Inc | Lung biomarkers and methods of use thereof |
| US20230213521A1 (en) * | 2020-04-28 | 2023-07-06 | Luxembourg Institute Of Health (Lih) | Biomarkers for detection of lung cancer |
| EP4208712A4 (en) * | 2020-09-01 | 2024-12-11 | Oncodea Corporation | PREDICTIVE DIAGNOSTIC TEST FOR EARLY DETECTION AND MONITORING OF DISEASE |
| CN112147099A (zh) * | 2020-09-22 | 2020-12-29 | 范庆坤 | 一种m蛋白紫外分光检测法 |
| KR20230080442A (ko) * | 2020-10-02 | 2023-06-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 폐암의 검출 및 치료를 위한 방법 |
| CN116529603A (zh) * | 2020-10-02 | 2023-08-01 | 德州大学系统董事会 | 用于检测和治疗肺癌的方法 |
| EP4237090B1 (en) * | 2020-10-29 | 2026-02-18 | Board of Regents, The University of Texas System | Methods for the detection and treatment of ovarian cancer |
| JP2024505333A (ja) | 2020-12-21 | 2024-02-06 | フリーノム ホールディングス，インク． | 結腸細胞増殖障害の早期検出のためのマーカー |
| AU2022249074A1 (en) | 2021-03-31 | 2023-09-21 | PrognomIQ, Inc. | Multi-omic assessment |
| GB2607436A (en) * | 2021-03-31 | 2022-12-07 | Prognomiq Inc | Multi-omic assessment |
| CN113267587B (zh) * | 2021-05-27 | 2023-11-10 | 杭州广科安德生物科技有限公司 | 测定pro-SFTPB标准物质含量的特征肽段及方法 |
| WO2023039479A1 (en) | 2021-09-10 | 2023-03-16 | PrognomIQ, Inc. | Direct classification of raw biomolecule measurement data |
| JP2024534992A (ja) | 2021-09-13 | 2024-09-26 | プログノミック インコーポレイテッド | 生体分子の増強された検出および定量 |
| EP4515242A1 (en) * | 2022-04-28 | 2025-03-05 | JANSSEN Pharmaceutica NV | Metabolite predictors for lung cancer |
| EP4357782A1 (en) * | 2022-10-18 | 2024-04-24 | MU Bioteknik Aktiebolag | Protein biomarker panel for the diagnosis of colorectal cancer |
| CN115575636B (zh) * | 2022-11-22 | 2023-04-04 | 杭州广科安德生物科技有限公司 | 一种用于肺癌检测的生物标志物及其系统 |
| CN116593702B (zh) * | 2023-05-11 | 2024-04-05 | 杭州广科安德生物科技有限公司 | 一种肺癌的生物标志物以及诊断系统 |
| EP4781412A2 (en) * | 2023-09-22 | 2026-07-29 | Board of Regents, The University of Texas System | Methods for the detection and treatment of lung cancer |
| CN118983078B (zh) * | 2024-08-15 | 2025-03-25 | 立本医疗器械(成都)有限公司 | 基于ptr-tof-ms的肺癌筛查模型构建方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080133141A1 (en) | 2005-12-22 | 2008-06-05 | Frost Stephen J | Weighted Scoring Methods and Use Thereof in Screening |
| EP3147665A1 (en) * | 2005-12-22 | 2017-03-29 | Abbott Molecular Inc. | Methods and marker combinations for screening for predisposition to lung cancer |
| US9347945B2 (en) | 2005-12-22 | 2016-05-24 | Abbott Molecular Inc. | Methods and marker combinations for screening for predisposition to lung cancer |
| WO2008144034A1 (en) | 2007-05-18 | 2008-11-27 | Duke University | Serum biomarkers for the early detection of lung cancer |
| JP2013525814A (ja) | 2010-05-07 | 2013-06-20 | アッヴィ・インコーポレイテッド | 標的化チロシンキナーゼインヒビターでの治療に対する感受性の予測方法 |
| WO2011162904A2 (en) * | 2010-05-24 | 2011-12-29 | Marek Malecki | Multidomain biotags for cancer detection, diagnosis and therapy and methods of their use priority statement |
| EP2577313A1 (en) | 2010-06-03 | 2013-04-10 | Porto Conte Ricerche S.r.l. | Biomarkers for lung neuroendocrine tumors |
| JP5905003B2 (ja) | 2010-07-09 | 2016-04-20 | ソマロジック・インコーポレーテッド | 肺癌バイオマーカーとその使用 |
| CN102321760A (zh) | 2011-08-26 | 2012-01-18 | 泸州医学院附属医院 | 一种非小细胞肺癌标志物及应用 |
| CA2799163C (en) * | 2011-12-18 | 2025-01-07 | 20/20 Genesystems, Inc. | Methods and algorithms for aiding in the detection of cancer |
| WO2013154998A1 (en) | 2012-04-09 | 2013-10-17 | Duke University | Serum biomarkers and pulmonary nodule size for the early detection of lung cancer |
| US20140271453A1 (en) | 2013-03-14 | 2014-09-18 | Abbott Laboratories | Methods for the early detection of lung cancer |
| US9753037B2 (en) * | 2013-03-15 | 2017-09-05 | Rush University Medical Center | Biomarker panel for detecting lung cancer |
| US20150072890A1 (en) | 2013-09-11 | 2015-03-12 | 20/20 Gene Systems, Inc. | Methods and compositions for aiding in the detection of lung cancer |
| US20160060329A1 (en) | 2014-07-28 | 2016-03-03 | Donald SIN | Compositions and methods for the diagnosis and prognosis of lung cancer |
| CN108139381A (zh) | 2015-06-26 | 2018-06-08 | 百奥马克癌症系统公司 | 肺癌检测方法 |
| WO2017155570A1 (en) | 2016-03-08 | 2017-09-14 | Magarray, Inc. | Protein and autoantibody biomarkers for the diagnosis and treatment of lung cancer |
| CN105717146B (zh) * | 2016-03-29 | 2018-11-09 | 复旦大学附属中山医院 | 一种基于ct影像及生物标志物谱针对中国城市人口高危人群的肺癌风险预测试剂盒 |
| CN109478231A (zh) | 2016-04-01 | 2019-03-15 | 20/20基因系统股份有限公司 | 帮助区别良性和恶性放射线照相明显肺结节的方法和组合物 |
| EP3361256A1 (en) | 2017-02-08 | 2018-08-15 | Fundación para la Investigación Médica Aplicada | In vitro method for the diagnosis of lung cancer |
| ES2995959T3 (en) | 2017-02-09 | 2025-02-11 | Univ Texas | Methods for the detection and treatment of lung cancer |
| KR20250047324A (ko) | 2017-08-07 | 2025-04-03 | 더 존스 홉킨스 유니버시티 | 암을 평가하고 치료하기 위한 방법 및 재료 |
| KR20230080442A (ko) | 2020-10-02 | 2023-06-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 폐암의 검출 및 치료를 위한 방법 |
| WO2024107923A1 (en) | 2022-11-17 | 2024-05-23 | Board Of Regents, The University Of Texas System | Methods for the detection and treatment of lung cancer |
| TR2022022101A2 (tr) | 2022-12-31 | 2023-04-24 | Atatuerk Ueniversitesi Fikri Muelkiyet Haklari Koordinatoerluegue Doener Sermaye Isletmesi | Nemlendi̇ri̇ci̇ modelaj örtüsü |
| JP2026520689A (ja) | 2023-05-31 | 2026-06-24 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 肺癌の検出及び治療方法 |
| EP4781412A2 (en) | 2023-09-22 | 2026-07-29 | Board of Regents, The University of Texas System | Methods for the detection and treatment of lung cancer |
-
2018
- 2018-02-09 ES ES18752036T patent/ES2995959T3/es active Active
- 2018-02-09 US US16/484,177 patent/US12504430B2/en active Active
- 2018-02-09 EP EP18752036.6A patent/EP3580560B1/en active Active
- 2018-02-09 EP EP24204031.9A patent/EP4528741A3/en not_active Withdrawn
- 2018-02-09 JP JP2019542716A patent/JP7311417B2/ja active Active
- 2018-02-09 CN CN201880010925.0A patent/CN110291397A/zh active Pending
- 2018-02-09 CN CN202311117176.0A patent/CN117368475A/zh active Pending
- 2018-02-09 CA CA3053116A patent/CA3053116A1/en active Pending
- 2018-02-09 KR KR1020247002923A patent/KR102827354B1/ko active Active
- 2018-02-09 KR KR1020197026040A patent/KR102630885B1/ko active Active
- 2018-02-09 WO PCT/US2018/017704 patent/WO2018148600A1/en not_active Ceased
-
2023
- 2023-03-28 US US18/191,506 patent/US12405274B2/en active Active
-
2025
- 2025-11-10 US US19/384,269 patent/US20260063638A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3053116A1 (en) | 2018-08-16 |
| KR102630885B1 (ko) | 2024-01-29 |
| US12405274B2 (en) | 2025-09-02 |
| WO2018148600A1 (en) | 2018-08-16 |
| EP3580560A4 (en) | 2020-12-09 |
| JP7311417B2 (ja) | 2023-07-19 |
| EP3580560A1 (en) | 2019-12-18 |
| US20260063638A1 (en) | 2026-03-05 |
| KR20190116368A (ko) | 2019-10-14 |
| US20200025766A1 (en) | 2020-01-23 |
| US12504430B2 (en) | 2025-12-23 |
| CN110291397A (zh) | 2019-09-27 |
| KR102827354B1 (ko) | 2025-06-30 |
| KR20240015172A (ko) | 2024-02-02 |
| JP2020510816A (ja) | 2020-04-09 |
| EP4528741A2 (en) | 2025-03-26 |
| EP3580560B1 (en) | 2024-10-02 |
| CN117368475A (zh) | 2024-01-09 |
| US20230314436A1 (en) | 2023-10-05 |
| EP4528741A3 (en) | 2025-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12405274B2 (en) | Methods for the detection and treatment of lung cancer | |
| Hollevoet et al. | Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis | |
| Rho et al. | Protein and glycomic plasma markers for early detection of adenoma and colon cancer | |
| Zhang et al. | The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients | |
| Filella et al. | Clinical usefulness of circulating tumor markers | |
| Amonkar et al. | Development and preliminary evaluation of a multivariate index assay for ovarian cancer | |
| Greillier et al. | Biomarkers for malignant pleural mesothelioma: current status | |
| Giessen et al. | Evaluation of preoperative serum markers for individual patient prognosis in stage I–III rectal cancer | |
| Hsu et al. | Serum markers of CYFRA 21-1 and C-reactive proteins in oral squamous cell carcinoma | |
| Moore et al. | Current clinical use of biomarkers for epithelial ovarian cancer | |
| WO2022072471A1 (en) | Methods for the detection and treatment of lung cancer | |
| van Veenendaal et al. | The Clinical Utility of Neuron-Specific Enolase (NSE) Serum Levels as a Biomarker for Merkel Cell Carcinoma (MCC) LM Veenendaal et al. | |
| Di Noia et al. | Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study | |
| Topuz et al. | Circulating calprotectin as a biomarker of laryngeal carcinoma | |
| JP2021144052A (ja) | マーカー、ヒト精巣上体タンパク質４（ｈｅ４）に基づく肺腺癌の再発を検出する方法および関連する使用 | |
| Nasir Kansestani et al. | Comparison of faecal protein biomarkers' diagnostic accuracy for colorectal advanced neoplasms: a systematic review and meta-analysis | |
| Wang et al. | The role of autoantibody detection in the diagnosis and staging of lung cancer | |
| WO2024107923A1 (en) | Methods for the detection and treatment of lung cancer | |
| Liu et al. | Albumin‐to‐alkaline phosphatase ratio: A novel prognostic index for patients with driver mutation‐negative advanced non‐small cell lung cancer | |
| Jannawan et al. | High level of serum coiled-coil domain containing 25 (CCDC25) as a diagnostic marker for cholangiocarcinoma but not for other cancers | |
| KR20260030760A (ko) | 폐암의 검출 및 치료 방법 | |
| CN121753110A (zh) | 肺癌检测方法 | |
| HK40105704A (en) | Methods for the detection and treatment of lung cancer | |
| Mayasari et al. | Correlation of CD 133 biomarker with outcomes and therapy response in advanced-stage non-small cell lung carcinoma | |
| Mallikarjuna et al. | Seven blood biomarkers are associated with TGF-β and VHL-HIF signaling in patients with clear cell renal cell carcinoma |